The U.S. FTC reaches a settlement with a pharmaceutical company and continues march “to set a standard for the industry” in pay-for-delay settlements cases (Cephalon)

KEYWORDS
Reference

U.S. District Court for the Eastern District of Pennsylvania, FTC / Cephalon, No. 2:08 - cv - 2141 - MSG, 28 May 2015, Proposed Stipulated Order for permanent injunction

Federal Trade Commission Continues March “to Set a Standard for the Industry” with Cephalon Settlement* On May 28, the Federal Trade Commission (“FTC”) announced it had reached a $1.2 billion settlement with Teva Pharmaceuticals, [1] which acquired Cephalon in 2012, over reverse payment for its narcolepsy drug, Provigil. The Cephalon settlement also has non-monetary terms that bar Cephalon from entering agreements that include (i) payments to a generic filer and (ii) an agreement by a generic filer not to develop or market a drug within 30 days of a patent settlement that impedes generic entry. [2] The FTC has lauded the outcome of Cephalon—its first settlement post-Actavis [3]—with FTC

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

Citation

Helen Cho Eckert, Jennifer M. Driscoll-Chippendale, The U.S. FTC reaches a settlement with a pharmaceutical company and continues march “to set a standard for the industry” in pay-for-delay settlements cases (Cephalon), 28 mai 2015, e-Competitions May 2015, Art. N° 74049

Visites 336

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues